DA
JAZZ icon

Denali Advisors’s Jazz Pharmaceuticals JAZZ Stock Holding History

Denali Advisors’s Portfolio JAZZ Stock Details JAZZ Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-14,400
Closed -$2.38M – 395
2020
Q4 		$2.38M Sell
14,400
-3,000
-17% -$447K 0.41% 88
2020
Q3 		$2.48M Sell
17,400
-9,600
-36% -$1.19M 0.49% 69
2020
Q2 		$2.98M Buy
27,000
+8,000
+42% +$885K 0.58% 51
2020
Q1 		$1.9M Buy
+19,000
New +$2.46M 0.41% 66
2019
Q4 		– Sell
-3,900
Closed -$500K – 334
2019
Q3 		$500K Sell
3,900
-200
-5% -$26.8K 0.07% 180
2019
Q2 		$584K Buy
+4,100
New +$551K 0.09% 142

Other funds holding JAZZ

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
LSV Asset Management
LSV Asset Management Chicago, Illinois $55.1B AUM 45.38% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

Denali Advisors's JAZZ Position: Q1 2021 in Review

Denali Advisors sold out of Jazz Pharmaceuticals (JAZZ) in Q1 2021, closing a stake of 14,400 shares — an estimated $2.38M sold.

Denali Advisors first reported a position in JAZZ in Q2 2019 and held it in 6 quarters. The position peaked at $2.98M in Q2 2020. 441 funds tracked by Wall St. Rank hold JAZZ as of Q1 2021.

  • Denali Advisors reported no remaining Jazz Pharmaceuticals position as of Q1 2021 after selling out during the quarter.
  • Denali Advisors sold 14,400 Jazz Pharmaceuticals shares in Q1 2021, an estimated $2.38M.
  • Denali Advisors first reported a position in Jazz Pharmaceuticals in Q2 2019 and held it in 6 quarters.
  • Denali Advisors's Jazz Pharmaceuticals position peaked at $2.98M in Q2 2020.
  • 441 funds tracked by Wall St. Rank held Jazz Pharmaceuticals as of Q1 2021.

Based on Denali Advisors's 13F filing for Q1 2021, filed 26 Apr 2021.